One of the great achievements of modern medical science is its ability to bring human life back from the brink of death. The Intensive Care Unit, or ICU, stands as a symbol of that achievement—a place where medical technology, professional skill, and dedicated care combine to create an intensive system for saving lives.
Yet if this very refuge of life-saving care becomes a source of new danger, it is undoubtedly a matter of deep concern.
A recent study conducted in several hospitals in Dhaka has revealed such a silent but serious threat: the spread of a drug-resistant fungus called Candida auris in ICUs.
Research conducted by icddr,b found that about seven percent of ICU patients carried this fungus. Even more alarming is that more than one-third of these patients became infected while staying in the ICU itself. In other words, a significant portion of the infections is spreading within the hospital environment.
When compared with international research, the seriousness of the situation becomes even clearer. In developed countries such as Canada or the United Arab Emirates, the infection rate is generally less than 0.5 percent, whereas in Dhaka’s hospitals it is many times higher.
Candida auris is often described by global health systems as a “superbug” because it has developed resistance to commonly used antifungal medications. Research shows that almost all strains are ineffective against widely used drugs such as fluconazole and voriconazole.
As a result, treatment becomes difficult, and the level of risk increases significantly for critically ill patients. Those who stay in the ICU for a long time, or who receive treatment through mechanical ventilation or various catheters, face an even greater risk of infection.
In the developed world, preventing hospital-acquired infections has long been considered a distinct public health priority. In many countries across Europe and North America, every major hospital operates an effective Infection Control Unit.
Their system is built on four pillars: assessing patients’ infection risks, regular screening, strict cleanliness, and training for healthcare workers. Bangladesh also has infection-prevention guidelines, but there are often gaps in their practical implementation. Overcrowded hospitals, limited infrastructure, insufficient training, and sometimes a lack of accountability all contribute to increased infection risks.
It is important to remember that Candida auris is not merely an isolated pathogen—it is a symbol of a broader challenge facing modern healthcare systems. The excessive and uncontrolled use of antibiotics and antifungal medications is turning antimicrobial resistance into a growing global crisis.
Sometimes, due to careless use by patients or even physicians, microorganisms gradually become stronger. What is easily treatable today may become a stubborn and incurable disease tomorrow.
Therefore, the first requirement in addressing this situation is awareness and discipline. Experts emphasize three crucial measures: regular cleaning with chlorine-based disinfectants, a strict hand-washing culture among healthcare workers, and routine screening of high-risk patients.
Secondly, it is essential to develop rational policies and restraint in the use of antifungal medications. In developed countries, “antimicrobial stewardship programs” monitor and regulate the use of such drugs. Bangladesh also needs similar structured systems. Thirdly, research and surveillance must be expanded.
The studies conducted in a few hospitals in Dhaka reveal only part of the problem. It is now important to determine how widely this fungus has spread in other hospitals across the country. Effective policymaking is impossible without proper data.
In truth, the fight against superbugs is not solely the responsibility of doctors—it is a collective responsibility. The sooner we recognize its importance, the sooner hospitals can once again become safe havens of healing. Otherwise, the seeds of invisible danger will continue to germinate within the very places meant for treatment and recovery.
